BCA
ANIP icon

Berman Capital Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Berman Capital Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+53
New +$1.65K ﹤0.01% 1797
2020
Q2 		– Sell
-33
Closed -$1K – 1598
2020
Q1 		$1K Buy
+33
New +$1.75K ﹤0.01% 1237

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Berman Capital Advisors's ANIP Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in ANI Pharmaceuticals (ANIP) in Q3 2021: 53 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1797 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in ANIP as recently as Q1 2020.

Berman Capital Advisors first reported a position in ANIP in Q1 2020 and has held it in 2 quarters since. 117 funds tracked by Wall St. Rank hold ANIP as of Q3 2021.

  • Berman Capital Advisors held 53 shares of ANI Pharmaceuticals worth $1K as of Q3 2021.
  • ANI Pharmaceuticals was a new Berman Capital Advisors position in Q3 2021.
  • ANI Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1797 holding.
  • Berman Capital Advisors first reported a position in ANI Pharmaceuticals in Q1 2020 and has held it in 2 quarters since.
  • 117 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.